Liva Nova将《2025财政年度收入指南》更新为每股3.65-3.75美元,略高于分析师的预期。 LivaNova updates FY2025 earnings guidance to $3.65-3.75 per share, slightly topping analysts' expectations.

医疗设备公司Liva Nova将其2025财政年度收入指南更新为每股3.65-3.75美元,略高于分析家的预期,预计收入为13亿美元。 LivaNova, a medical device company, updated its FY2025 earnings guidance to $3.65-3.75 per share, slightly above analysts' expectations, with revenue forecast at $1.3 billion. 尽管达到52周的低点,分析师仍维持“Buy”共识,目标价格调整各异。 Despite hitting a 52-week low, analysts maintain a "Buy" consensus, with varied target price adjustments. 董事Francesco Bianchi最近出售了1 250股股份,将所有权减少了14.25%。 Director Francesco Bianchi recently sold 1,250 shares, reducing his ownership by 14.25%. Liva Nova通过心肺、神经调节和高级循环支持部门运作。 LivaNova operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments.